Two posters at the American Association of Cancer Research 2020 (AACR 2020) on TK1 and AroCell TK 210 ELISA has now been published online.
The content of the posters has previously been released as an abstract and now the complete posters can be read on AACR’s website.
The first poster has the title “Serum Thymidine Kinase 1 levels predict prostate cancer-specific survival” and is based on a study by Teemu Murtola of Tampere University Hospital. The poster describes the use of Thymidine Kinase 1 as a prognostic marker for the progression of prostate cancer after diagnosis.
The second poster's title is “Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during 5-fluoruracil treatment.” by Jagarlamudi KK et al, demonstrates how the immunoassay of Thymidine Kinase 1 can be used to study anti-cancer drug effects in a clinically relevant animal model.